Different therapies other than Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma: Safety and effectiveness

Different therapies other than Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma: Safety and effectiveness - Different therapies other than Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma: Safety and effectiveness

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005848

Enrollment

Registered

2011-08-01

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.TACE-refractoy and TACE-failure advanced HCC patients 2.Patients with different therapies except sorafenib

Exclusion criteria

Exclusion criteria: 1.Patients with contraindiation for the use of the drugs

Design outcomes

Primary

Measure	Time frame
progression free survival	—

Secondary

Measure	Time frame
time to progression, time to treatment failure, overall survival, response rate, disease control rate, safety	—

Countries

Japan

Contacts

Public ContactKohta Iguchi

Kyoto university hospital surgery

iguchik@kuhp.kyoto-u.ac.jp075-751-3242

Outcome results